Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-07

FDA Approved: QUVIVIQ — Original Application (Idorsia Pharmaceuticals Ltd)

View source ↗

Summary

FDA approves QUVIVIQ (daridorexant) from Idorsia as an Original Application for treating insomnia in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QUVIVIQ (daridorexant)

Snippet

ORIG AP for QUVIVIQ (DARIDOREXANT)